Neurological soft signs (NSS) are nonspecific indicators of brain dysfunction that are found to be in excess and correlated with cognitive dysfunction and psychopathology hi patients with schizophrenia. The aim of the study was to examine whether the severity of NSS determines the efficacy of atypical antipsychotics hi schizophrenia. Forty-three patients with schizophrenia were assessed on psychopathology and cognitive domains of executive functioning, memory, attention, and psychomotor speed at baseline and 6 months after they had been switched from typical to atypical antipsychotics. NSS were examined at baseline. The high-NSS group showed more severe psychopathology and greater impaired cognitive function than the low-NSS group at baseline. Following treatment, there were improvements hi cognitive functioning and psychopathology with the low-NSS group, which showed significant improvements on measures of verbal fluency, memory, and psychomotor speed and negative symptoms. The high-NSS group also showed improvements on most of these measures, but the improvement was less than that seen in the low-NSS group. The presence of high NSS in schizophrenia patients impedes the improvement in cognitive function with atypical antipsychotics treatment
NSS are nonspecific indicators of brain dysfunction that are not localizable to specific brain areas and are found with greater prevalence in patients with schizophrenia (Heinrichs and Buchanan 1988) . NSS have also been associated with negative or deficit symptoms (Buchanan et al. 1990; Merriam et al. 1990 ), poor outcome (Johnstone et al. 1990 ), low psychosocial performance (Wong et al. 1997) , and an earlier onset of illness (Quitkin et al. 1976) in schizophrenia.
The significance of NSS in schizophrenia is not clear, but it has been proposed that these signs may be a familial vulnerability marker for the illness, possibly reflecting genetic factors, and that neurodevelopmental brain injury leads to an increased prevalence of these signs (Fish 1977; Parnas et al. 1982; King et al. 1991; Griffiths et al. 1998) .
Schizophrenia patients often exhibit profound neuropsychological deficits when compared to healthy people (Sharma 1999) . Studies have also shown a relationship between NSS and general cognitive dysfunction (Arango et al. 1999) , specifically on tasks measuring prefrontal cortical dysfunction (Mohr et al. 1996) , timed motor speed, and motor coordination (Flashman et al. 1996) . Conventional antipsychotic drugs have potent therapeutic actions on psychotic positive symptoms but produce no or very small improvement on cognitive dysfunction in schizophrenia (Meltzer and McGurk 1999) . Preliminary studies have supported the notion that atypical antipsychotics may be superior to typical antipsychotics in improving various domains of cognitive function in schizophrenia (Keefe et al. 1999; Sharma 1999; Harvey and Keefe 2001) .
Treatment effects or side effects of medications do not appear to explain the presence of NSS in schizophre-Psychiatric Assessments. Psychopathology in patients was assessed by experienced clinical researchers (M.D., W.S., and B.B.) using the Positive and Negative Syndrome Scale (PANSS; Kay et al. 1987) . Interrater reliability was determined in a separate sample of three schizophrenia patients. Criteria for reliability was that scoring of each symptom was within one point and that there was at least 80 percent agreement on the total score for the PANSS and on each of the three subscales: positive, negative, and general psychopathology.
Cognitive Assessments. A comprehensive neuropsychological test battery (see table 1 for details) was completed on both occasions of testing, except that the Wechsler Adult Intelligence Scale-Revised (WAIS-R; Wechsler 1981 ) and the National Adult Reading Test (NART; Nelson 1982) were completed at only occasion 1 by a psychologist blind to NSS and symptom ratings. All neuropsychological tests were completed within 7 days of the PANSS rating. The cognitive battery included standardized tests that have been widely used in schizophrenia research. Measures of premorbid intelligence included an aggregate of the scores obtained from NART, a test of reading ability in which irregular words of increasing difficulty are read aloud and the number of errors made provides an estimate of premorbid intelligence. Current intellectual ability was assessed by the WAIS-R.
Executive function. Measures of executive function included the Wisconsin Card Sorting Test (WCST; Heaton 
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1993) and Verbal Fluency (letters) (Benton et al. 1983) . WCST measures abstraction and set changing. Verbal Fluency (letters) provides a measure of spontaneous word generation (left frontal lobe functioning). Memory. Verbal memory was assessed using the logical memory subtest of the Wechsler Logical Memory (Immediate and Delayed) (WMS; Wechsler 1945, immediate and delayed recall of two short stories) and the Hopkins Verbal Memory Test (a simple list learning test providing information on immediate and delayed recall) (Brandt 1991) . Nonverbal memory was assessed using the visual reproduction subtest of WMS-immediate and delayed recall of three designs.
Attention. In this version of the Continuous Performance Test (Conners 1995) , subjects are told to respond to every letter stimulus except X. The test yields measures of reaction time for all target responses and of how well the individual discriminated between targets and nontargets (attentiveness). Omission errors are number of targets missed, and commission errors are number of nontargets responded to.
Psychomotor functioning. This was assessed using Computerised Trails, part B (Morris 1995) and the Digit Symbol Substitution Test from WAIS-R. All tasks require some level of attention, motor coordination, and visual tracking.
Statistical Analysis. Patients were compared with controls for age, gender, ethnicity, years of education, IQ, and cognitive functions. Given that there was a significant difference between the patients and controls on the variable of years of education (table 2), differences between the two groups for cognitive measures were evaluated using analysis of covariance, with the years of education as a covariate.
Patients were divided into two groups (high and low NSS) on the basis of median split (median = 7; median included in the low-NSS group) on the total score on the 24 soft signs assessed. Chi-square tests were used to examine any differences between the low-and high-NSS groups for categorical variables (gender, ethnicity, handedness, marital status, and medication) and t tests for differences between the two groups on the remaining demographic variables. The effects of NSS in mediating the cognitive and clinical efficacy were examined using a series of analyses of covariance with change scores (i.e., baseline score-score at 6-month followup) on various clinical and cognitive measures (separately) as dependent variables and the baseline scores of psychopathology and cognition as covariates. This was done to examine differential improvement in the low-and high-NSS group, while controlling for the poor baseline performance in the high-NSS group. All the analysis was repeated using die additional covariate of full-scale IQ. To examine the relationship of NSS scores to improvement in cognition and psychopathology, Pearson's correlation was used. An exploratory analysis examined whether improvements in the high and low group in cognition and psychopathology were explained by the type of atypical antipsychotic used (risperidone, olanzapine, clozapine) using multivariate analysis of variance and also with multivariate analysis of covariance using number of NSS as a covariate. All analyses were carried out using uie SPSS Windows package (version 8). The alpha level for significance testing was set at 0.05.
Results

Cognitive Functioning: Patients Versus Controls.
Ranges of normal scores and observed scores in me normal controls and patients on the neuropsychological tests at baseline are shown in table 1.
Patients were impaired as compared to controls on all cognitive tests except on premorbid IQ, WCST, Continuous Performance Test, and Trail Making Test, controlling for the years of education (table 3) .
Demographics, Antipsychotic Medication, and IQ: Low-Versus High-NSS Groups. There were 21 subjects in the high-NSS group and 22 in the low-NSS group; mean NSS for the entire group was 6.31 (SD 3.36). There were no significant differences in age, years of education, duration of illness, and gender between the two groups (table 2). There was no relationship between the duration of illness, age, years of education, and either the number of soft signs present or the total NSS score. The low-and high-NSS groups did not differ on doses of typical antipsychotic at baseline. The high-and low-NSS groups had comparable numbers of subjects on atypical antipsychotic medications, and the doses in the two groups were not significantly different. Means (SDs) in milligrams for doses of atypical antipsychotics in the high-NSS group were as follows: risperidone 6.42 (1.13), olanzapine 18.33 (2.58), and clozapine 534 (204.82). Similar mean doses were seen in the low-NSS group: risperidone 5.77 (1.04), olanzapine 16.87 (3.72), and clozapine 560 (67.54). Fullscale IQ and premorbid IQ were, however, significantly lower in the high-NSS group than in the low-NSS group. Controls had significantly higher IQ (full-scale) and years of education than both the low-and high-NSS groups (table 2) .
Symptom Ratings: Occasion 1 Versus Occasion 2. The high-NSS group showed severe symptomatology as compared to the low-NSS group on both occasions. Both groups improved on symptoms from occasion 1 to occasion 2 with greater improvement in the low-NSS than in the high-NSS group, although this was not formally significant for positive symptoms (table 4) . No differential improvement in the two groups was apparent when fullscale IQ was used as a covariate in addition to baseline scores.
Relationship Between Cognitive Functioning and NSS
Subscales. There were no significant correlations between various cognitive measures at baseline and NSS subscale scores apart from an inverse correlation between the sequencing subscale and nonverbal memory scores (r > 0.46, p< 0.001).
Change in Cognitive Functioning: Occasion 1 Versus Occasion 2. The z scores of neuropsychological tests at baseline and 6 months for the high and low groups are depicted in figure 1 and figure 2 . The high-NSS group underperformed on all tests as compared to the low-NSS group on occasion 1 (baseline), although this failed to reach significance for measures on the Continuous Performance Test and the Hopkins memory test-recognition component and delayed recall (table 5) .
There was an improvement from occasion 1 to occasion 2 in both the low-and the high-NSS groups, but the rate of improvement was significantly greater in the low-NSS group on Verbal Fluency, Hopkins verbal recognition memory, visual reproduction delayed memory, and digit symbol, with a strong trend for such effect on visual reproduction immediate memory and verbal memory delayed recall. There was no differential improvement on Continuous Performance Test, WCST, Verbal memory immediate recall, Hopkins immediate/delayed memory, and Trail Making test (table 5) .
The rate of improvement was significantly greater in the low-NSS group as compared to the high-NSS group on digit symbol (F = 6.54, df= 41, p = 0.01) and Verbal Fluency (F = 7.47, df = 41, p = 0.01) when full-scale IQ was used as a covariate in addition to baseline scores. No significant differential improvement was apparent for other cognitive variables.
Relationship between change in cognitive functioning and psychopathology and NSS scores. There was a positive correlation between the improvement score of Digit symbol age-equivalent score (r = 0.43, p = 0.005) and NSS score. No other correlations were found to be significant Differential effects of three atypical antipsychotics on cognition. There was no differential effect of the three various atypical antipsychotics on cognitive functioning. When number of NSS was used as a covariate, the effects remained nonsignificant.
Differential effects of three atypical antipsychotics on psychopathology. There was a trend for an overall effect of atypical antipsychotics on psychopathology (F = 1.902, df = 6,76, p = 0.09). Significant group differences were observed for negative symptoms (F = 6.145, df = 2A3, p = 0.005) and PANSS total score (F = 4.114, df = 2,43, p = 0.024). Bonferroni post hoc tests showed a superior effect of clozapine over risperidone on negative symptoms (p = 0.001) and PANSS total score (p = 0.007).
The effects remained the same when the analyses were controlled for the number of NSS.
Discussion
The main findings of the study were as follows: (1) the high-NSS group was more symptomatic than the low-NSS group; (2) both low-and high-NSS groups improved on symptoms with atypical antipsychotics treatment; (3) patients, as a group, performed worse than controls, replicating numerous previous findings of cognitive deficits in schizophrenia; (4) high-NSS patients showed significantly more impaired cognitive performance than low-NSS patients; (5) there was an improvement in cognitive functioning with atypical antipsychotics treatment; and (6) most important, as hypothesized, greater improvements on cognitive and clinical measures were seen in the low-NSS group as compared to the high-NSS group, which, in addition, appeared to be mediated by baseline IQ.
Our finding of higher psychopathology scores in the high-NSS group is in line with previous findings showing that these signs correlate with negative or deficit symptoms (Buchanan et al. 1990; Vaid et al. 1993; Smith and Kadewari 1996) and a poorer outcome (Johnstone et al. 1990 ). The mean number (6.3) of NSS in this study was also comparable to that seen in previous studies (Boks et al. 2000) . There is no literature on what constitutes higher levels of NSS, and therefore the decision to divide the patients into high and low NSS on the basis of number of NSS rated was based on the empirical data derived from the present study, on the presumption that a higher number of NSS would indicate severe brain pathology.
Our finding of both the low and high groups improving on symptoms with atypical antipsychotics treatment is also in line with a recent study (Smith et al. 1999fc ). Previous studies, mostly using small samples, reported no correlation between NSS and short-or intermediate-term outcome with traditional neuroleptics (Kolakowska et al. 1985; Buchanan et al. 1994) or with the atypical neuroleptic clozapine (Buchanan et al. 1994 ). However, a study by Smith and Kadewari (1996) reported that severity of NSS correlated negatively with degree of reduction in positive symptoms in chronically hospitalized and nonresponding schizophrenia patients who were given a trial of risperidone. In a later study, Smith et al. (1999a) demonstrated that differences in the number and severity of NSS strongly differentiated between chronic schizophrenia patients who were (1) responders to conventional neuroleptics and (2) nonresponders to mese medications. Our study perhaps was more powerful because it used patients who needed a change in current medication and thus were switched to atypical antipsychotics. The association of NSS with negative symptoms is consistent with results from previous studies that have reported higher NSS scores in deficit compared with nondeficit schizophrenia patients (Buchanan et al. 1990 ) and a relationship of negative symptom measures with NSS scores (Merriam et al. 1990; Andreasen et al. 1994 ). Our study demonstrated that patients with high NSS scores failed to show an equivalent improvement in comparison to those with low NSS scores. This may support the notion that NSS are subtle expressions of brain damage (Parnas et al. 1982 ) that relate to higher levels of negative symptoms that may not be very amenable to atypical antipsychotics treatment.
The differential effects of the atypical antipsychotics on cognition and psychopathology could not be conclusively determined in this study because the study involved a small number of subjects on different antipsychotics. However, an exploratory analysis revealed that the various atypical antipsychotics had no differential effect on cognition.
In our study, patients with high NSS ratings showed greater impairment on all domains of cognitive functions (IQ, executive function, memory, attention, psychomotor functioning) than the patients with low NSS ratings. This suggests that there is a relationship between severity of soft signs and cognitive functions. Patients in both groups showed improvement over 6 months with the atypical antipsychotics treatment. However, the low-NSS group showed greater improvement on certain primarily frontal lobe functions, such as the Verbal Fluency test; temporal lobe functions, such as Hopkins memory test recognition component, and nonverbal memory; and on digit symbol, which is sensitive to multiple aspects of brain dysfunction.
Digit symbol is a test of psychomotor performance that is relatively unaffected by intellectual prowess, memory, or learning. It is more sensitive to brain damage than other WAIS battery subtests in that its score is most likely to be depressed even when damage is minimal (Lezak (Miceli et al. 1981) , particularly the left frontal lobe, but scores on this test can also be affected by subcortical dysfunction in the basal ganglia. Thus, findings from our study suggest that patients with high NSS show a disproportionately lower improvement with atypical neuroleptics on domains of psychomotor performance, and the Verbal Fluency test, which taps frontal lobe function. It may be argued that significant improvement in cognitive functions on these tasks was due to practice and not due to a change to atypical antipsychotics treatment If so, the high-NSS group failed to show this effect. However, the observations that NSS not only related to the improvements on cognitive measures but also to clinical improvement suggest that the severity of NSS can mediate responsiveness to atypical antipsychotic medication and that higher NSS may be an indicator of poor treatment outcome.
Also of significance are the findings of disproportionately lower improvement in various memory tests in the high-NSS group. This relationship of NSS and change on memory tests following antipsychotic treatment has not been reported. However, a study by Arango et al. (1999) reported that the "others" subscale from the Neurological Evaluation Scale (Buchanan and Heinrichs 1989 ) (which includes short-term memory) was the most highly discriminating subscale in classifying a group of patients with schizophrenia. Our patients with high NSS scores failed to show the expected improvement on tests of both verbal and nonverbal (visual) memory. The functional localization of neural substrates of memory is to the temporal lobe; more specifically, nonverbal memory is localized to the right temporal lobe and verbal memory to the left temporal lobe (Lezak 1983) . However, previous studies examining the relationship between NSS and cognitive functions did not report a relationship with memory functioning on cognitive tests (Flashman et al. 1996; Mohr et al. 1996) . Our study, however, was different in that the relationship was examined in the context of change of cognitive functions with treatment that was not examined by previous studies. The relationship of memory with the brain dysfunction that is reflected as NSS may be subtle and apparent only when examined in the background of the potentially marked cognitive function change that can be associated with atypical antipsychotics treatment.
The findings in this study have to be examined keeping in view that there was no differential symptomatic improvement in either of the groups and in the cognitive domain significant findings only persisted for the variable of digit symbol and Verbal Fluency, when full scale IQ was used as a covariate. This finding raises two important possibilities. First, baseline IQ might be an important determinant of improvement in cognitive functions with atypical antipsychotics in the low-NSS group and, by inference, might also mediate responses to other therapeutic agents relevant to the treatment of cognitive disturbances in this illness. Second, the persistence of a differential improvement on Verbal Fluency and digit symbol in the low-NSS group after covarying for IQ suggests that improvement in executive and psychomotor functioning may be more specific and over and above the general improvements seen in other domains, which were reduced when the analyses controlled for baseline IQ.
Most previous studies looking at the relationship of NSS to cognitive function have used a cross-sectional approach. Our study had a different approach examining cognition in high-and low-NSS groups and its response to atypical antipsychotics over a period of time. It remains to be seen whether the effect of NSS is different for various atypical antipsychotics. Recent reviews of literature (Keefe et al. 1999; Sharma 1999; Harvey and Keefe 2001) suggest that novel antipsychotics when compared with conventional antipsychotics improve cognitive functions in schizophrenia; however, the results of the studies need to be interpreted in light of the methodological problems. There is recent evidence that clozapine and risperidone may improve attention/information processing and executive functions (Kumari et al. 1999; Meltzer and McGurk 1999; Yee et al. 1998 ) as well as normalization of relevant brain functions (Honey et al. 1999) . There are also preliminary data that olanzapine may have beneficial cognitive effects (Meltzer and McGurk 1999) . In our sample, it is difficult to differentiate the individual effect on cognition of the three atypical antipsychotics, clozapine, risperidone, and olanzapine, and its relationship to NSS because of small numbers of patients on these drugs.
The severity of NSS may indicate prior brain insults or injuries undetected in early life, and intrauterine or perinatal etiologies have been proposed for these signs (Pamas et al. 1982) . As there is evidence emerging that schizophrenia is a neurodevelopmental disorder, the severity of NSS may indicate the degree of neurodevelopmental brain damage (King et al. 1991) . Our finding that patients with high NSS scores do not show the expected improvement in cognitive functions in spite of being on atypical antipsychotics may indicate that an optimal amount of underlying brain functioning is necessary for the benefits in cognition that may occur with atypical antipsychotics to accrue.
It is now recognized that improvement in cognitive functions along widi symptoms is important for an overall improved clinical state in patients (Sharma 1999 Patients with more NSS who are likely to suffer from more brain dysfunction are more vulnerable to side effects of antipsychotic medication, as shown in a study by Convit et al. (1994) where patients with more NSS showed side effects with relatively low doses of haloperidol. Thus, it is likely that some of the improvement in symptoms and cognition may be due to a reduction in side effects following withdrawal of typical antipsychotics. We were not able to determine this because side effects to antipsychotic medication were not rated in this study. However, there is recent evidence that atypical antipsychotics have been associated with improvements in cognitive functioning independent of their effects on extrapyramidal symptoms (Weiser et al. 2000 ). An ideal control group for this study would have been a cohort of chronic schizophrenia patients maintained on their typical antipsychotics to assess whether cognition or NSS change over time. Also, this study involved small sample sizes, patients were followed up on cognition and clinical symptoms up to only 6 months, and NSS was not assessed at followup. It is not yet known whether atypical antipsychotics influence the stability of NSS over time, although NSS have been found to be relatively stable over time in patients with schizophrenia (Smith et al. 1999a) . Future studies could address these possibilities.
